MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer

Satoshi Fukagawa, Kohei Miyata, Fusanori Yotsumoto, Chihiro Kiyoshima, Sung Ouk Nam, Haruchika Anan, Takahiro Katsuda, Daisuke Miyahara, Masaharu Murata, Hiroshi Yagi, Kyoko Shirota, Shin'ichiro Yasunaga, Kiyoko Kato, Shingo Miyamoto

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT-PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR-135a-3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.

Original languageEnglish
Pages (from-to)886-896
Number of pages11
JournalCancer Science
Issue number5
Publication statusPublished - May 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer'. Together they form a unique fingerprint.

Cite this